220193-83-9

Upstream product

• 220193-60-2 {4-[2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl]-benzyl}-phosphonic acid di-tert-butyl ester 
• 220193-52-2 (2S)-2-amino-N₁-[3-(1-naphthalenyl)propyl]butanediamide 
• 220193-51-1 {1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexyl}-carbamic acid tert-butyl ester 

Downstream Products

• 220193-81-7 N-{1-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-2-[4-(di-tert-butoxy-phosphorylmethyl)-phenyl]-ethyl}-oxalamic acid tert-butyl ester 
• 220193-87-3 N-[(S)-1-{1-[(S)-2-Carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-2-(4-phosphonomethyl-phenyl)-ethyl]-oxalamic acid 
• 364630-80-8 [4-(2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-2-{2-[1-(4-methoxy-benzyl)-1H-tetrazol-5-yl]-acetylamino}-ethyl)-benzyl]-phosphonic acid di-tert-butyl ester 

Relevant academic research and scientific papers

Potent inhibition of Grb2 SH2 domain binding by non-phosphate- containing ligands

Development of Grb2 Src homology 2 (SH2) domain binding inhibitors has important implications for treatment of a variety of diseases, including several cancers. In cellular studies, inhibitors of Grb2 SH2 domain binding have to date been large, highly cha